CoreCap Advisors’s 10x Genomics TXG Stock Holding History

CoreCap Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Hold	52	–	–	﹤0.01%	2533
2026 Q1	$1.1K	Hold	52	–	–	﹤0.01%	2522
2025 Q4	$848	Buy	52 +50	+2,500%	+$755	﹤0.01%	2626
2025 Q3	$23	Hold	2	–	–	﹤0.01%	2769
2025 Q2	$23	Sell	2 -39	-95%	-$355	﹤0.01%	2731
2025 Q1	$358	Buy	41 +39	+1,950%	+$492	﹤0.01%	2776
2024 Q4	$29	Hold	2	–	–	﹤0.01%	2813
2024 Q3	$45	Hold	2	–	–	﹤0.01%	2580
2024 Q2	$39	Hold	2	–	–	﹤0.01%	1560
2024 Q1	$75	Buy	+2	New	+$88	﹤0.01%	2460
2022 Q4	$146	Buy	+4	New	+$131	﹤0.01%	2288
2022 Q3	–	Sell	-4	Closed	–	–	1983
2022 Q2	$0	Buy	+4	New	+$208	﹤0.01%	2277
2022 Q1	–	Sell	-5	Closed	-$1K	–	1987
2021 Q4	$1K	Buy	+5	New	+$766	﹤0.01%	2262

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CoreCap Advisors's TXG Position: Q2 2026 in Review

CoreCap Advisors held its 10x Genomics (TXG) position steady in Q2 2026 at 52 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

CoreCap Advisors first reported a position in TXG in Q4 2021 and has held it in 13 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

CoreCap Advisors held 52 shares of 10x Genomics worth $1.99K as of Q2 2026.
CoreCap Advisors left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2533 holding.
CoreCap Advisors first reported a position in 10x Genomics in Q4 2021 and has held it in 13 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.